Risks and benefits of continued aggressive statin therapy

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, known as statins, are widely used to lower cholesterol.
• Clinical trials confirm statins' efficacy in reducing cardiovascular risk for primary and secondary prevention.

Purpose of the Study:

• To evaluate the effectiveness of statins in reducing low-density lipoprotein cholesterol (LDL-C) and overall cardiovascular risk.
• To assess the safety profile of statin therapy, including potential adverse effects like myopathy and liver enzyme elevations.

Main Methods:

• Analysis of extensive clinical trial data on statin use in diverse patient populations.
• Review of established definitions and clinical guidelines for statin-induced adverse events.

Main Results:

• Statins significantly reduce fatal and nonfatal cardiovascular events across various patient groups, including women and the elderly.
• Cardiovascular risk reduction was observed even in patients with LDL-C levels below 2.6 mmol/l (100 mg/dl) and across a broad range of baseline cholesterol levels.
• Rare but serious complications include rhabdomyolysis, while dose-dependent transaminase elevations occur in a small percentage of patients.

Conclusions:

• Statins offer substantial cardiovascular benefits with a low risk of serious adverse effects.
• Aggressive statin therapy should be strongly considered for patients at high risk of coronary heart disease.